LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study

Julien Mazières, T.M. Kim, Boon Khaw Lim, Marie Wislez, Christophe Dooms, Giovanna Finocchiaro, H. Hayashi, Chong Kin Liam, Jo Raskin, L.M. Tho, Filippo de Marinis, Ernest Nadal, Ewoud J. Smit, Xiao‐Feng Le, Sabine Brutlach, A.M. OBrate Grupp, Svenja Adrian, Barbara Ellers‐Lenz, Niki Karachaliou, Yi‐Long Wu